Structure Therapeutics Prices $650 Million Upsized Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Upsized Offering: Structure Therapeutics announced the pricing of 8,461,538 American depositary shares at $65 each, expecting gross proceeds of approximately $650 million, reflecting strong market demand for its novel oral small molecule therapeutics.
- Pre-Funded Warrants: The offering includes 1,538,462 pre-funded warrants priced at $64.9999 each, enhancing investor participation and potentially providing additional funding for the company.
- Strong Underwriter Lineup: Notable financial institutions such as Jefferies, Goldman Sachs, and Morgan Stanley are acting as joint book-running managers, boosting market confidence in the transaction and ensuring a smooth completion.
- Future Growth Potential: The offering is expected to close on December 11, 2025, with proceeds aimed at supporting the company's R&D in metabolic diseases, further solidifying its competitive position in the biopharmaceutical industry.
GPCR.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 74.00 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.980
Low
50.00
Averages
74.00
High
100.00
Current: 69.980
Low
50.00
Averages
74.00
High
100.00
Citi
Samantha Semenkow
Buy
maintain
$60 -> $100
2025-12-09
New
Reason
Citi
Samantha Semenkow
Price Target
$60 -> $100
2025-12-09
New
maintain
Buy
Reason
Citi analyst Samantha Semenkow raised the firm's price target on Structure Therapeutics to $100 from $60 and keeps a Buy rating on the shares. The positive Phase 2b data for aleniglipron gives Structure an attractive oral obesity asset, the analyst tells investors in a research note. The firm sees the drug getting "significant interest from strategics" looking to enter the oral obesity market. Citi believes aleniglipron showed "potential best-in-class" weight loss with competitive tolerability.
Morgan Stanley
Terence Flynn
Overweight
maintain
$120
2025-12-08
New
Reason
Morgan Stanley
Terence Flynn
Price Target
$120
2025-12-08
New
maintain
Overweight
Reason
After Structure Therapeutics (GPCR) announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity, Morgan Stanley analyst Terence Flynn argues that 36-week data from the core Phase 2b ACCESS study "appear competitive" with Eli Lilly's (LLY) orforglipron. The firm, which models an aleniglipron U.S. launch in 2028 and 2040 worldwide unadjusted sales of $6.3B, has an Overweight rating and $120 price target on Structure shares.
H.C. Wainwright
H.C. Wainwright
maintain
$60
2025-12-08
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$60
2025-12-08
New
maintain
Reason
After Structure Therapeutics (GPCR) released pivotal topline data from the Phase 2b ACCESS program, H.C. Wainwright argues that the clean safety profile along with 15.3% placebo-adjusted weight loss at the 240 mg dose shatters the "oral ceiling," exceeding the roughly 12.4% efficacy benchmark set by Eli Lilly's (LLY) orforglipron. The firm, which sees the data validating the "bull case" thesis the firm previously outlined, has a Buy rating and $60 price target on Structure shares.
Stifel
NULL -> Buy
maintain
$50 -> $90
2025-12-08
New
Reason
Stifel
Price Target
$50 -> $90
2025-12-08
New
maintain
NULL -> Buy
Reason
Stifel raised the firm's price target on Structure Therapeutics to $90 from $50 and keeps a Buy rating on the shares after both of the ACCESS and ACCESS-II trials confirmed aleniglipron's dose-dependent potency and importantly improved safety profile. Structure "now has a viable and versatile small-molecule offering for independent development or future partnership," the analyst tells investors.
See All Ratings
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?